Biocentury reported that GDF15 is emerging as the lead target in cancer-associated cachexia development, with Pfizer and CatalYm both advancing programs through Phase II/III studies. GDF15 is a cytokine at the center of pathways linked to muscle wasting, and the target is framed as a way to address both tumor immune interactions and systemic metabolic decline. The pipeline positioning signals that developers are converging on a single mechanistic node for cachexia, where historically few therapies have demonstrated consistent clinical impact. As combination and sequencing strategies mature, GDF15 inhibitors may become key components in supportive oncology regimens. For biotech and pharma, cachexia remains a high-need area with complex trial endpoints, making late-stage progress around a specific target particularly consequential for competitive positioning.